Want to see JP:4512 full AI Analyst Report?

Wakamoto Pharmaceutical Co., Ltd. (4512) Price & Analysis

0 Followers

4512 Stock Chart & Stats

¥286.00

-¥4.00(-1.79%)

At close: Jan 08 4:00 PM EST

¥286.00

-¥4.00(-1.79%)

Day’s Range― - ―

52-Week Range¥240.00 - ¥380.00

Previous CloseN/A

Volume100.70K

Average Volume (3M)49.42K

Market Cap

¥10.34B

Enterprise Value¥7.82K

Total Cash (Recent Filing)¥3.56B

Total Debt (Recent Filing)¥100.00M

Price to Earnings (P/E)30.2

Beta0.46

Next Earnings

Nov 09, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield1.17%

Share Statistics

EPS (TTM)-5.12

Shares Outstanding34,838,326

10 Day Avg. Volume32,550

30 Day Avg. Volume49,423

Financial Highlights & Ratios

PEG Ratio0.21

Price to Book (P/B)1.01

Price to Sales (P/S)1.23

P/FCF Ratio-11.59

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Strong Revenue Growth And Latest-year ProfitabilityThe latest annual period combined strong revenue growth with positive EBIT and net income, showing that the business can regain profitability while expanding sales. This provides a stronger operating base for the next several quarters, although consistency remains important.

Conservatively Financed Balance SheetVery low leverage reduces financial risk and leaves the company with flexibility to fund operations, absorb weaker periods, or pursue investments without heavy debt service. The large equity base is a durable balance-sheet advantage over the next several quarters.

Stable Gross Margins Support Product EconomicsA fairly stable gross margin in the high-40% range indicates that product economics have held up across periods rather than depending entirely on temporary cost benefits. This supports reinvestment capacity and gives the business some protection against operating volatility.

Bears Say

Persistent Negative Operating And Free Cash FlowThree consecutive years of negative operating and free cash flow weaken earnings quality and can require the company to draw on cash reserves despite low leverage. If sustained, this pattern could constrain investment, dividends, and the ability to self-fund growth.

Thin Net Margins Limit Earnings ResilienceA net margin of roughly 2% leaves limited room for higher costs, weaker demand, or execution setbacks before profits are materially affected. Thin bottom-line conversion also means that strong sales growth may not translate proportionally into durable earnings or cash generation.

Volatile Operating Performance And Low Returns On EquityRepeated periods of losses or negative EBIT, combined with low returns on equity, indicate that the substantial capital base has not yet produced consistently attractive profitability. This execution volatility reduces confidence that recent improvement will persist through the next business cycle.

4512 FAQ

What was Wakamoto Pharmaceutical Co., Ltd.’s price range in the past 12 months?

Wakamoto Pharmaceutical Co., Ltd. lowest stock price was ¥240.00 and its highest was ¥380.00 in the past 12 months.

What is Wakamoto Pharmaceutical Co., Ltd.’s market cap?

Wakamoto Pharmaceutical Co., Ltd.’s market cap is ¥10.34B.

When is Wakamoto Pharmaceutical Co., Ltd.’s upcoming earnings report date?

Wakamoto Pharmaceutical Co., Ltd.’s upcoming earnings report date is Nov 09, 2026 which is in 47 days.

How were Wakamoto Pharmaceutical Co., Ltd.’s earnings last quarter?

Wakamoto Pharmaceutical Co., Ltd. released its earnings results on Aug 05, 2026. The company reported ¥0.19 earnings per share for the quarter.

Is Wakamoto Pharmaceutical Co., Ltd. overvalued?

According to Wall Street analysts Wakamoto Pharmaceutical Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Wakamoto Pharmaceutical Co., Ltd. pay dividends?

Wakamoto Pharmaceutical Co., Ltd. pays a Annually dividend of ¥3.5 which represents an annual dividend yield of 1.17%. See more information on Wakamoto Pharmaceutical Co., Ltd. dividends here

What is Wakamoto Pharmaceutical Co., Ltd.’s EPS estimate?

Wakamoto Pharmaceutical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Wakamoto Pharmaceutical Co., Ltd. have?

Wakamoto Pharmaceutical Co., Ltd. has 34,838,326 shares outstanding.

What happened to Wakamoto Pharmaceutical Co., Ltd.’s price movement after its last earnings report?

Wakamoto Pharmaceutical Co., Ltd. reported an EPS of ¥0.19 in its last earnings report. Following the earnings report the stock price went up 2.23%.

Which hedge fund is a major shareholder of Wakamoto Pharmaceutical Co., Ltd.?

Currently, no hedge funds are holding shares in JP:4512

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Wakamoto Pharmaceutical Co., Ltd.

Headquartered in Tokyo, Japan, Wakamoto Pharmaceutical Co., Ltd. specializes in the production and distribution of both prescription and over-the-counter pharmaceuticals across the country. Their diverse offerings include Strong Wakamoto, a widely recognized gastrointestinal aid formulated to enhance digestion, regulate intestinal health, and supplement nutrition. Additionally, the company provides AVANTBISE oral tablets, a dietary supplement designed to rebalance the oral microbiome, as well as various medicated toothpastes. Founded in 1929, the enterprise was initially known as Society for Nutrition and Raising Children Co., Ltd. before formally changing its name to Wakamoto Pharmaceutical Co., Ltd. in July 1943.